OnKure Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

OnKure Therapeutics (Nasdaq: OKUR) announced that President and CEO Nicholas Saccomano, Ph.D. will present and hold one-on-one investor meetings at three investor conferences in November–December 2025.

Scheduled appearances: a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on Nov 10, 2025 at 4:00 p.m. ET; a corporate presentation at the Stifel Healthcare Conference in New York on Nov 12, 2025 at 4:00 p.m. ET; and a fireside chat at the Evercore Healthcare Conference in Miami on Dec 3, 2025 at 12:30 p.m. ET. Live audio webcasts will be available for each event and replays will be posted on the company website for 30 days after the events.

BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link.
  
  
• A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link.
  
  
• A fireside chat at the Evercore Healthcare Conference, in Miami on December 3, 2025, at 12:30 p.m. ET. A live audio webcast will be available through this link.
  
  

Following the events, replays will be available on the OnKure website (click here) for 30 days.

About OnKure Therapeutics

OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα^H1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic or pathologically activated PI3Kα and has multiple programs designed to enable best-in-class targeting of this key disease creating gene.

For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.

Contact:

Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com

FAQ

When will OnKure Therapeutics (OKUR) present at the Guggenheim Healthcare Innovation Conference?

OnKure will hold a fireside chat on Nov 10, 2025 at 4:00 p.m. ET with a live audio webcast.

How can investors watch OnKure's (OKUR) Stifel Healthcare Conference presentation on Nov 12, 2025?

A live audio webcast will be available for the Nov 12, 2025 at 4:00 p.m. ET corporate presentation.

Will OnKure Therapeutics (OKUR) take meetings at the Evercore Healthcare Conference on Dec 3, 2025?

Yes. The CEO will do a fireside chat on Dec 3, 2025 at 12:30 p.m. ET and will be available for one-on-one investor meetings.

Are replays of OnKure (OKUR) conference presentations available after the events?

Yes. Replays will be posted on the company website and available for 30 days after each event.

Where can I find the live audio webcast links for OnKure (OKUR) conference appearances?

Live audio webcasts are available through the links provided for each conference and via the company's investor relations webcasts.